A boutique life sciences management consulting firm that bridges business and science focusing on new product development, market access, and go-to-market strategy for breakthrough therapeutics & gene therapy. GS & Partners works with top executives and management teams across an array of biotech companies and VC firms (GRIFFINGSPEIZER.COM).

A collective industry effort to fight poverty, advance science education and provide job training throughout Greater Philadelphia. Member of fundraising and finance committee (LIFESCIENCECARES.ORG).

Venture-backed biotech positioned to become a global leader in gene therapy. Member of Commercial Leadership Team (NASDAQ: ORTX).

Publicly traded biopharmaceutical company focusing on breakthrough orphan products for rare neurological disorders. Member of Commercial Leadership Team (NASDAQ: SCMP).

Commercial development leader MK-8931 Merck's investigational PIII/PII BACE inhibitor for Alzheimer's (NYSE:MRK).

Served as Chief Marketing Officer for Eastern Europe, Middle East & Africa. Accountable for $1.6B pharmaceutical & vaccine business. Led marketing organization in setting and extending marketing strategy across enterprise-wide portfolio, aligning strategy and resource allocation across markets, products, and disease areas.

Head of New Products for Merck's General Medicine Business. Led Team of New Product Directors and accountable for multiple therapeutic areas including: neuroscience, chronic & acute pain, severe asthma & COPD. Identified the global marketing potential and requirements for commercial success for compound(s) pre-clinical through Phase IIb.

Led Merck's co-promotion / co-marketing agreement with Nycomed to launch DAXAS® a novel treatment option for chronic obstructive pulmonary disease (COPD) in the EU and Canada. Served as member of the Joint Steering Committee and led cross company collaborations to prepare for the Launch of DAXAS® in EUCAN with estimated peak sales of $300M; accountable for global P&L management.